Simultaneously targeting the transcription and degradation machines of RRM2 more significantly decreases the protein level, which could be a new therapeutic strategy for more effective treatment of CRC, in addition to conventional inhibition of RR enzymatic activity, or the double downregulation of RRM2 level could promote CRC more sensitive to the enzyme activity inhibition (Fig. 5J). The gene discussed is RRM2; the disease is colorectal carcinoma.